Research

Innovative peptide therapeutics for age-related disease.

The program is in its design stage. What follows is what we are building, and the reasoning behind it.

New molecules, validated targets

Each planned program pairs a molecule of our own design with a target that approved medicines have already validated in patients. That leaves the chemistry as the open question, and chemistry is the part design work can address directly.

One platform, several directions

The peptide technology underneath is designed for repeated use. One platform, built around stability and delivery, is meant to support several programs over time, each in a different area of age-related disease. Lessons from one program, on design and on manufacture, carry into the next.

Stability and delivery

Most peptides fail on practical grounds. They break down too quickly, or they never reach the tissue they were meant for. Our design work centers on half-life, stability, and delivery for that reason: these properties decide whether a peptide can become a medicine at all.

Staged development

Programs will advance in stages. Design comes first, then testing, then the longer work of development. We will state where the program stands at each stage. Today it stands at the beginning.

Writing

The reasoning behind this program is set out in Insights, our series on peptide science.